محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| التنسيق: | Recurso digital |
| اللغة: | |
| منشور في: |
Zenodo
2025
|
| الوصول للمادة أونلاين: | https://doi.org/10.5281/zenodo.14635746 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
جدول المحتويات:
- <p>The high rate of brain metastasis in patients with non-small cell and small cell lung cancer demands discovery of novel therapeutic targets to treat lymph node metastasis which serves as an intermediate to the CNS (central nervous system) (1-5). We recently utilized whole transcriptome technologies to define the full complement of differentially expressed kinases and phosphatases in HER2+ breast cancer: in the primary tumor, and in metastasis to the CNS (6-8). Here we utilize whole transcriptome technologies (9, 10) to measure total transcription in the lymph node metastases of humans with small cell and non-small cell lung cancer. We describe here a therapeutic target that is up-regulated and differentially expressed in lymph node metastasis in humans with small cell and non-small cell lung cancer, BAALC, as a candidate therapeutic target for the medical management of lymph node metastasis in human lung cancer. </p>